GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

GlaxoSmithKline (GSK) has appointed its consumer health leader, Emma Walmsley, to take over as CEO when Sir Andrew Witty retires next year. Walmsley has a background in marketing, and joined GSK ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Emma Walmsley Searching for “fewer and more focused priorities, to have bigger launches,” will be a priority according to Walmsley, who worked in marketing and management at L’Oreal for 17 ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F.

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.

Emma Walmsley would like to see Prime Minister Narendra Modi creating a nutrition programme similar to the cleanliness drive Swachh Bharat. Get updates on your preferred social platform Follow us ...